Intensity-Modulated Radiation Therapy with Simultaneous Integrated Boost Combined with Concurrent Chemotherapy for the Treatment of Anal Cancer Patients: 4-Year Results of a Consecutive Case Series

REFERENCES

• Shank B. Treatment of anal canal carcinoma. Cancer 1985; 55:2156–2162.
   PubMed Web of Science ®Google Scholar
• Green J, Schaupp W, Cantril S. Anal carcinoma: Therapeutic concepts. Am J Surg 1980;140:151–155.
   PubMed Web of Science ®Google Scholar
• Lestrade L, De Bari B, Pommier P, Montbarbon X, Lavergne E, Ardiet JM, Carrie C. Role of brachytherapy in the treatment of cancer of the anal canal. Long-term follow-up and multivariate analysis of a large monocentric retrospective experience. Strahlenther Onkol 2014;190:546–554.
   PubMed Web of Science ®Google Scholar
• Nigro ND. An evaluation of combined therapy for squamous cell cancer of the anal canal. Dis Colon Rectum 1984;27:763–766.
   PubMed Web of Science ®Google Scholar
• UKCCCR Anal cancer Trial Working Party. UK Co-ordination Committee on Cancer Research: Epidermoid anal cancer: Results from the UKCCCR randomized trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. Lancet 1996;348:1049–1054.
   PubMed Web of Science ®Google Scholar
• Bartelink H, Roelofsen F, Eschwege F, Rougier P, Bosset JF, Gonzalez DG, Peiffert D, van Glabbeke M, Pierart M. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: Results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Group. J Clin Oncol 1997;15:2040–2049.
   PubMed Web of Science ®Google Scholar
• Gunderson LL, Winter KA, Ajani JA, Pedersen JE, Moughan J, Benson AB 3rd, Thomas CR Jr, Mayer RJ, Haddock MG, Rich TA, Willett CG. Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: Survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomicyn versus fluorouracil/cisplatin. J Clin Oncol 2012;30:4344–4351.
   PubMed Web of Science ®Google Scholar
• Milano MT, Jani AB, Farrey KJ, Rash C, Heimann R, Chmura S. Intensity-modulated radiation therapy (IMRT) in the treatment of anal cancer. Int J Radiat Oncol Biol Phys 2005;63:354–361.
   PubMed Web of Science ®Google Scholar
• Salama JK, Mell LK, Schomas DA, Miller RC, Devisetty K, Jani AB, Mundt AJ, Roeske JC, Liauw Sl, Chmura SJ. Concurrent chemotherapy and intensity modulated radiation therapy for anal cancer patients: a multicenter experience. J Clin Oncol 2007;25:4581–4586.
   PubMed Web of Science ®Google Scholar
• Mell LK, Schomas DA, Salama JK, Devisetty K, Aydogan B, Miller RC, Jani AB, Kindler HL, Mundt AJ, Roeske JC, Chmura SJ. Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 2008;70:1431–1437.
   PubMed Web of Science ®Google Scholar
• Alongi F, Fiorino C, Cozzarini C, Broggi S, Perna L, Cattaneo GM, Calandrino R, Di Muzio N. IMRT significantly reduces acute toxicity of whole-pelvis irradiation in patients treated with post-operative adjuvant or salvage radiotherapy after radical prostatectomy. Radiother Oncol 2009;93:207–212.
   PubMed Web of Science ®Google Scholar
• Mistrangelo M, Pelosi E, Bello’ M, Ricardi U, Milanesi E, Cassoni P, Baccega M, Filippini C, Racca P, Lesca A, Munoz FH, Skanjeti A, Cravero F, Morino M. Role of positron emission tomography-computed tomography in the management of anal cancer. Int J Radiat Oncol Biol Phys 2012;84:66–72.
   PubMed Web of Science ®Google Scholar
• Mistrangelo DM, Bello’ M, Cassoni P, Milanesi E, Racca P, Munoz F, Rondi N, Gibo N, Senetta R, Ricardi U, Morino M. Value of staging squamous cell carcinoma of the anal margin and canal using the sentinel lymph node procedure: An update of the series and a review of the literature. Br J Cancer 2013;108:527–532.
   PubMed Web of Science ®Google Scholar
• Myerson RJ, Garofalo MC, El Naqa I, Abrams RA, Apte A, Bosch WR, Das P, Gunderson LL, Hong TS, Kim JJ, Willet CG, Kachnic LA. Elective clinical target volumes for conformal therapy in anorectal cancer: A radiation therapy oncology consensus panel contouring atlas. Int J Radiat Oncol Biol Phys 2009;74:824–830.
   PubMed Web of Science ®Google Scholar
• Ng M, Leong T, Chander S, Chu J, Kneebone A, Carroll S, Wiltshire K, Ngan S, Kachnic L. Australasian Gastrointestinal Trials Group (AGITG) contouring atlas and planning guidelines for intensity-modulated radiotherapy in anal cancer. Int J Radiat Oncol Biol Phys 2012;83:1455–1462.
   PubMed Web of Science ®Google Scholar
• Kachnic LA, Tsai HK, Coen JJ, Blaszkowsky LS, Hartshorn K, Kwak EL, Willins JD, Ryan DP, Hong TS. Dose-painted intensity-modulated radiation therapy for anal cancer: A multi-institutional report of acute toxicity and response to therapy. Int J Radiat Oncol Biol Phys 2012;82:153–158.
   PubMed Web of Science ®Google Scholar
• Viellot S, Fenoglietto P, Lemanski C, Llacer Moscardo C, Gourgou S, Dubois J-B, Aillers N, Azria D. IMRT for locally advanced anal cancer: Clinical experience of the Montpellier Cancer Center. Radiat Oncol 2012;7:45.
   PubMed Web of Science ®Google Scholar
• Menkarions C, Azria D, Laliberte B, Moscardo CL, Gourgou S, Lemanski C, Dubois JB, Ailleres N, Fenoglietto P. Optimal organ-sparing intensity-modulated radiation therapy (IMRT) regimen for the treatment of locally advanced anal canal carcinoma: A comparison of conventional and IMRT plans. Radiat Oncol 2007; 2:41.
   PubMed Web of Science ®Google Scholar
• Fiorino C, Alongi F, Perna L, Brossi S, Cattaneo GM, Cozzarini C, Di Muzio N, Fazio F, Calandrino R. Dose-volume relationships for acute bowel toxicity in patients treated with pelvic nodal irradiation for prostate cancer. Int J Radiat Oncol Biol Phys 2009;75:29–35.
   PubMed Web of Science ®Google Scholar
• Ajani JA, Winter KA, Gunderson LL, Pedersen J, Benson AB 3rd, Thomas CR Jr, Mayer RJ, Haddock MG, Rich TA, Willett C. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: A randomized controlled trial. JAMA 2008;299:1914–1921.
   PubMed Web of Science ®Google Scholar
• Flam M, John M, Pajak TF, Petrelli N, Myerson R, Doggett S, Quivery J, Rotman M, Kerman H, Coia L, Murray K. Role of mytomicin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol 1996;14:2527–2539.
   PubMed Web of Science ®Google Scholar
• Mell LK, Kochanski JD, Roeske JC, Haslam JJ, Mehta N, Yamada SD, Hurteau JA, Collins YC, Lengyel E, Mundt AJ. Dosimetric predictors of acute hematologic toxicity in cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy. Int J Radiat Oncol Biol Phys 2006;66:1356–1365.
   PubMed Web of Science ®Google Scholar
• Kachnic LA, Winter K, Myerson RJ, Goodyear MD, Willins J, Esthappan J, Haddock MG, Rotman M, Parikh PJ, Safran H, Willett CG. RTOG 0529: A phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mytomycin C for the reduction of acute morbidity in carcinoma of the anal canal. Int J Radiat Oncol Biol Phys 2013;86:27–33.
   PubMed Web of Science ®Google Scholar
• Herman JM, Thomas CR Jr. RTOG 0529: Intensity modulated radiation therapy and anal cancer, a step in the right direction? Int J Radiat Oncol Biol Phys 2013;86:8–10.
   PubMed Web of Science ®Google Scholar
• De Bari B, Buglione M, Maddalo M, Lestrade L, Spiazzi L, Vitali P, Barbera F, Magrini SM: External beam radiotherapy ± chemotherapy in the treatment of anal canal cancer: A single institute long-term experience on 100 patients. Cancer Invest 2014;32:248–255.
   PubMed Web of Science ®Google Scholar
• Orlandi E, Palazzi M, Pignoli E, Fallai C, Giostra A, Olmi P. Radiobiological basis and clinical results of the simultaneous integrated boost (SIB) in intensity modulated radiotherapy (IMRT) for head and neck cancer: A review. Crit Rev Oncol Hematol 2010;73:111–125.
   PubMed Web of Science ®Google Scholar
• Franco P, Zeverino M, Migliaccio F, Cante D, Sciacero P, Casanova Borca V, Torielli P, Arrichiello C, Girelli G, La Porta MR, Tofani S, Numico G, Ricardi U. Intensity-modulated and hypofractionated simultaneous integrated boost adjuvant breast radiation employing static ports of tomotherapy (TomoDirect): a prospective phase II trial. J Cancer Res Clin Oncol 2014;140:167–177.
   PubMed Web of Science ®Google Scholar
• Franco P, Cante D, Sciacero P, Girelli G, La Porta MR, Ricardi U. Tumor bed boost integration during whole breast radiotherapy: A review of the current evidence. Breast Care 2015;10:44–49.
   PubMed Web of Science ®Google Scholar
• Call JA, Haddock MG, Quevedo JF, Larson DW, Miller RC. Intensity-modulated radiotherapy for squamous cell carcinoma of the anal canal: Efficacy of a low daily dose to clinically negative regions. Radiat Oncol 2011;6:134.
   PubMed Web of Science ®Google Scholar